Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
CA77.1 [CMA Activator]
100
CHF
CHF 100.00
In stock
AG-CR1-0165-M0055 mgCHF 100.00
AG-CR1-0165-M02525 mgCHF 400.00
| Product Details | |
|---|---|
| Synonyms | N-[4-(6-Chloroquinoxalin-2-yl)phenyl]acetamide |
| Product Type | Chemical |
| Properties | |
| Formula |
C16H12ClN3O |
| MW | 297.7 |
| CAS | 2412270-22-3 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (20mg/ml). Almost insoluble in other tested solvents, like MeOH, EtOH or water. |
| Identity | Determined by 1H-NMR. |
| InChi Key | ZQXMPDVGBWOTBY-UHFFFAOYSA-N |
| Smiles | ClC1=CC=C(N=C(C2=CC=C(NC(C)=O)C=C2)C=N3)C3=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- CA77.1 is a novel selective chaperone-mediated autophagy (CMA) activator by increasing the expression of the lysosomal receptor for this pathway, LAMP2A, in lysosomes. Chaperone-mediated autophagy (CMA), is a selective autophagy shown to degrade neurodegeneration-related proteins such as α-synuclein (α-syn) or tau. Loss of neuronal CMA leads to altered neuronal function, selective changes in the neuronal metastable proteome and proteotoxicity. Chemical upregulation of CMA has been shown to ameliorate pathology in AD experimental mouse models, reduce brain pathology and improve disease phenotype.
- CA77.1 is able to activate CMA in vitro and in vivo (in contrary to it's derivative AR7 which was not suitable for in vivo application). CA77.1 is able to activate CMA in vivo, and demonstrates brain penetrance and favorable pharmacokinetics. It has been shown in animal studies that administration of CA77.1 to enhance chaperone-mediated autophagy, may help to degrade toxic pathogenic protein products such as tau proteins and has potential applications in the treatment of Alzheimer's disease.
Product References
- Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome: M. Bourdenx, et al.; Cell 184, (2021)
Related Products
